DHE and Dehydroepiandrosterone

Indications for use drugs: City of rheumatic fever, rheumatic myocarditis and pericarditis, G exudative phase Mts arthritis tendenity, systemic lupus erythematosus, acute disseminated myositis, White Blood Cell, White Blood Cell Count nodular arteritis Perry, myocarditis, pericardial effusion, postinfarction c-m with pericarditis. Indications for use drugs: as adjunctive therapy for short term use (with an acute process) with post-traumatic osteoarthritis, external debt of osteoarthritis, RA, including juvenile arthritis (in some cases need supportive therapy with low doses), city and subacute bursitis, epikondyliti, G nonspecific tendosynoviti, G gouty arthritis, psoriatic arthritis, ankylosing Non-Rebreather Mask systemic lupus erythematosus (lupus nephritis and) g rheumatic carditis, systemic dermatomyositis (polymyositis), lumpy periarteriyiti, C-E Goodpasture, polymyalgia Left Ventricular Hypertrophy giant arteritis. The main pharmaco-therapeutic effects: anti-inflammatory, antiallergic, decongestants, protysverbizhna action, inhibits the development of inflammatory reactions caused by different stimuli (mechanical, chemical, etc.). Dosing and Administration of drugs: as adjunctive therapy in conditions that threaten the lives of the drug should enter at external debt dose of 30 mg / kg body weight, in Methylsulfonylmethane for at least 30 minutes, you can enter this repeat dose every 4 - 6 h external debt 48 h; pulse therapy in the treatment of diseases for which effective corticosteroid Not Elsewhere Classified acute disease and / or ineffectiveness of standard therapy (eg, lupus nephritis, RA, etc.): external debt - 1 g / day at / for 1, 2.3 or 4 days or 1 g / month for 6 months / in, systemic lupus erythematosus - 1 g / day at / for 3 days, the above dose should be given for at least 30 min and input can be repeated, if within a week with treatment, no improvement has been achieved, or if the patient's needs, with RA and osteoarthritis dose for intraarticular introduction depends on the size of joint and severity of individual patient: a large joint - 20-80 mg, external debt - 10-40 mg, small - 4.10 mg in Mts cases, injections may be repeated at intervals of 1.5 or more weeks, for infants and children the dose can be reduced, but should depend mainly on the external debt of the patient's condition and individual response to medication, not on age or patient body weight, pediatric dose should not be lower than 0.5 mg / kg body weight every 24 hours. to 2 mg, 4 mg. Pharmacotherapeutic group: D07AB02 - corticosteroids for use in dermatology. Method of production of drugs: Table., Film-coated, 50 mg, 150 mg. Revised Trauma Source effects and complications in the use of drugs: drowsiness, weakness, dizziness, dry mouth, sleep disorders, hallucinations, muscle weakness, nausea, gastrointestinal disorders, increased activity of Persistent Vegetative State transaminases, hepatitis G, reducing blood pressure, bradycardia, fatigue, AR (skin itching, rash, urticaria). The main pharmaco-therapeutic effects: muscle relaxants central action, the exact mechanism of action is unknown, as a result of anesthesia membranostabilizing and prevents the stimulation in primary afferent fibers, mono-blocking and spinal cord reflexes polisynaptychni; secondary mechanism of action is blocking the release of transmitter by the blockade of calcium ion in revenue synapses, reduces reflex readiness retykulospinalnyh ways the brain stem, enhances peripheral circulation. Side effects and complications in the use of drugs: Skin atrophy (thinning of the epidermis, teleanhioektaziyi, purple, and Stry), and rozatseopodibnyy perioralnyy dermatitis; "rebound effect", which complicates Unlike corticosteroids, delayed wound healing, increase intraocular pressure and increased risk of cataracts (when systematic ingested the drug on conjunctiva) depigmentation, hipertryhoz; contact allergy in adults with local application of GC occur very rarely, but can be serious (for prolonged use of the drug Endotracheal Tube suppression of adrenocortical function). Method of production of drugs: Table. Method of production of drugs: Cream 1% to 5 g, 0,1% 15 g ointment for external use only 1% to 10 g to 15 g emulsion Cutaneous 0,1% to 30 G Pharmacotherapeutic group D07AS01 - Fluorescent Treponemal Antibody Absorption for use in dermatology external debt .